Molecular analysis and modeling of inactivation of human CYP2D6 by four mechanism based inactivators

Drug Metabolism Letters

Volumn 6, Issue 1, 2012, Pages 7-14

  Livezey, Mara ^a   Nagy, Leslie D ^a   Diffenderfer, Laura E ^a   Arthur, Evan J ^a   Hsi, David J ^a   Holton, Jeffrey M ^a   Furge, Laura Lowe ^a  

^a KALAMAZOO COLLEGE   (United States)

Author keywords

CYP2D6; EMTPP; MDMA; Mechanism based inactivation; Paroxetine; SCH66712

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 5 FLUORO 2 [4 [(2 PHENYL 1H IMIDAZOL 5 YL)METHYL] 1 PIPERAZINYL]PYRIMIDINE; ALANINE; AROMATIC COMPOUND; CYTOCHROME P450 2D6; ENZYME INHIBITOR; IMIDAZOLE; LEUCINE; NITROGEN; PAROXETINE; PHENYLALANINE; PIPERAZINE; THREONINE; UNCLASSIFIED DRUG; [1 (2 ETHYL 4 METHYL 1H IMIDAZOL 5 YL) METHYL] 4 [4 (TRIFLUOROMETHYL) 2 PYRIDINYL]PIPERAZINE; 1 ((2 ETHYL 4 METHYL 1H IMIDAZOL 5 YL)METHYL) 4 (4 (TRIFLUOROMETHYL) 2 PYRIDINYL)PIPERAZINE; 1-((2-ETHYL-4-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(4-(TRIFLUOROMETHYL)-2-PYRIDINYL)PIPERAZINE; IMIDAZOLE DERIVATIVE; LIGAND; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; SCH 66712;

ARTICLE; AYURVEDA; BINDING AFFINITY; BLACK PEPPER; CONTROLLED STUDY; DRUG METABOLISM; DRUG POTENCY; DRUG STRUCTURE; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME METABOLISM; FOOD INTAKE; HUMAN; LIGAND BINDING; MOLECULAR DOCKING; MOLECULAR MODEL; PRIORITY JOURNAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; METABOLISM;

CYTOCHROME P-450 CYP2D6; ENZYME INHIBITORS; HUMANS; IMIDAZOLES; LIGANDS; MODELS, MOLECULAR; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PAROXETINE; PYRIDINES; PYRIMIDINES;

EID: 84864960138     PISSN: 18723128     EISSN: None     Source Type: Journal    
DOI: 10.2174/187231212800229318     Document Type: Article

References (31)

1. Guengerich, F. P., Cytochromes P450, drugs, and diseases. Mol. Interv., 2003, 3, 194-204.
2. Hollenberg, P. F.; Kent, U. M.; Bumpus, N. N., Mechanism-based inactivation of human cytochromes p450s: experimental characterization, reactive intermediates, and clinical implications. Chem. Res. Toxicol., 2008, 21, 189-205.
3. Wolff, T.; Distlerath, L. M.; Worthington, M. T.; Groopman, J. D.; Hammons, G. J.; Kadlubar, F. F.; Prough, R. A.; Martin, M. V.; Guengerich, F. P., Substrate specificity of human liver cytochrome P-450 debrisoquine 4-hydroxylase probed using immunochemical inhibition and chemical modeling. Cancer Res., 1985, 45, 2116-22.
4. Islam, S. A.; Wolf, C. R.; Lennard, M. S.; Sternberg, M. J., A three-dimensional molecular template for substrates of human cytochrome P450 involved in debrisoquine 4-hydroxylation. Carcinogenesis, 1991, 12, 2211-9.
5. Koymans, L.; Vermeulen, N. P.; van Acker, S. A.; te Koppele, J. M.; Heykants, J. J.; Lavrijsen, K.; Meuldermans, W.; Donne-Op den Kelder, G. M., A predictive model for substrates of cytochrome P450-debrisoquine (2D6). Chem. Res. Toxicol., 1992, 5, 211-9.
6. Rowland, P.; Blaney, F. E.; Smyth, M. G.; Jones, J. J.; Leydon, V. R.; Oxbrow, A. K.; Lewis, C. J.; Tennant, M. G.; Modi, S.; Eggleston, D. S.; Chenery, R. J.; Bridges, A. M., Crystal structure of human cytochrome P450 2D6. J. Biol. Chem., 2006, 281, 7614-22.
7. Guengerich, F. P.; Miller, G. P.; Hanna, I. H.; Martin, M. V.; Leger, S.; Black, C.; Chauret, N.; Silva, J. M.; Trimble, L. A.; Yergey, J. A.; Nicoll-Griffith, D. A., Diversity in the oxidation of substrates by cytochrome P450 2D6: lack of an obligatory role of aspartate 301-substrate electrostatic bonding. Biochemistry, 2002, 41, 11025-34.
8. Gonzalez, F. J.; Skoda, R. C.; Kimura, S.; Umeno, M.; Zanger, U. M.; Nebert, D. W.; Gelboin, H. V.; Hardwick, J. P.; Meyer, U. A., Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature, 1988, 331, 442-6.
9. Palamanda, J. R.; Casciano, C. N.; Norton, L. A.; Clement, R. P.; Favreau, L. V.; Lin, C.; Nomeir, A. A., Mechanism-based inactivation of CYP2D6 by 5-fluoro-2-[4-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-piperazinyl]pyrimidine. Drug Metab. Dispo., 2001, 29, 863-7.
10. Bertelsen, K. M.; Venkatakrishnan, K.; Von Moltke, L. L.; Obach, R. S.; Greenblatt, D. J., Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab. Dispos., 2003, 31, 289-93.
11. Heydari, A.; Yeo, K. R.; Lennard, M. S.; Ellis, S. W.; Tucker, G. T.; Rostami-Hodjegan, A., Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine. Drug Metab. Dispos., 2004, 32, 1213-7.
12. Hutzler, J. M.; Steenwyk, R. C.; Smith, E. B.; Walker, G. S.; Wienkers, L. C., Mechanism-based inactivation of cytochrome P450 2D6 by 1-[(2-ethyl-4-methyl-1H-imidazol-5-yl)methyl]-4-[4-(trifluoromethyl)-2-pyridinyl]piperazine: kinetic characterization and evidence for apoprotein adduction. Chem. Res. Toxicol., 2004, 17, 174-84.
13. Nagy, L. D.; Mocny, C. S.; Diffenderfer, L. E.; Hsi, D. J.; Butler, B. F.; Arthur, E. J.; Fletke, K. J.; Palamanda, J. R.; Nomeir, A. A.; Furge, L. L., Substituted imidazole of 5-fluoro-2-[4-[(2-phenyl-1Himidazol-5-yl)methyl]-1-piperazinyl]pyrimidine Inactivates cytochrome P450 2D6 by protein adduction. Drug Metab. Dispos., 2011, 39, 974-83.
14. Subehan; Usia, T.; Kadota, S.; Tezuka, Y., Mechanism-based inhibition of human liver microsomal cytochrome P450 2D6 (CYP2D6) by alkamides of Piper nigrum. Planta Med., 2006, 72, 527-32.
15. Desta, Z.; Wu, G. M.; Morocho, A. M.; Flockhart, D. A., The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6. Drug Metab. Dispos.,2002, 30, 336-43.
16. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J., Automated docking using a Lamarckian genetic algorithm and empirical binding free energy function. J. Computational Chem., 1998, 19, 1639-1662.
17. Huey, R.; Morris, G. M.; Olson, A. J.; Goodsell, D. S., A semiempirical free energy force field with charge-based desolvation. J. Computational Chem., 2007, 28, 1145-1152.
18. Farre, M.; Abanades, S.; Roset, P. N.; Peiro, A. M.; Torrens, M.; O'Mathuna, B.; Segura, M.; de la Torre, R., Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics. J. Pharmacol. Exp. Ther., 2007, 323, 954-62.
19. Ramamoorthy, Y.; Yu, A. M.; Suh, N.; Haining, R. L.; Tyndale, R. F.; Sellers, E. M., Reduced (+/-)-3,4-methylenedioxymethamphetamine ("Ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro. Biochem. Pharmacol., 2002, 63, 2111-9.
20. Obach, R. S.; Walsky, R. L.; Venkatakrishnan, K., Mechanismbased inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions. Drug Metab. Dispos., 2007, 35, 246-55.
21. Keizers, P. H.; de Graaf, C.; de Kanter, F. J.; Oostenbrink, C.; Feenstra, K. A.; Commandeur, J. N.; Vermeulen, N. P., Metabolic regio-and stereoselectivity of cytochrome P450 2D6 towards 3,4-methylenedioxy-N-alkylamphetamines: in silico predictions and experimental validation. J. Med. Chem.,2005, 48, 6117-27.
22. Keizers, P. H.; Schraven, L. H.; de Graaf, C.; Hidestrand, M.; Ingelman-Sundberg, M.; van Dijk, B. R.; Vermeulen, N. P.; Commandeur, J. N., Role of the conserved threonine 309 in mechanism of oxidation by cytochrome P450 2D6. Biochem. Biophys. Res. Commun., 2005, 338, 1065-74.
23. Silverman, R. B., Mechanism-based Enzyme Inactivation: Chemistry and Enzymology. CRC Press: Boca Raton, FL, 1988; Vol. 1.
24. Lim, H. K.; Duczak, N., Jr.; Brougham, L.; Elliot, M.; Patel, K.; Chan, K., Automated screening with confirmation of mechanismbased inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes. Drug Metab. Dispos., 2005, 33, 1211-9.
25. Atal, C. K.; Zutshi, U.; Rao, P. G., Scientific evidence on the role of Ayurvedic herbals on bioavailability of drugs. J. Ethnopharmacol., 1981, 4, 229-32.
26. Lala, L. G.; D'Mello, P. M.; Naik, S. R., Pharmacokinetic and pharmacodynamic studies on interaction of "Trikatu" with diclofenac sodium. J. Ethnopharmacol., 2004, 91, 277-80.
27. Subehan; Usia, T.; Iwata, H.; Kadota, S.; Tezuka, Y., Mechanismbased inhibition of CYP3A4 and CYP2D6 by Indonesian medicinal plants. J. Ethnopharmacol., 2006, 105, 449-55.
28. Subehan; Usia, T.; Kadota, S.; Tezuka, Y., Constituents of Zingiber aromaticum and their CYP3A4 and CYP2D6 inhibitory activity. Chem. Pharm. Bull (Tokyo), 2005, 53, 333-5.
29. Sridhar, J.; Jin, P.; Liu, J.; Foroozesh, M.; Stevens, C. L., In silico studies of polyaromatic hydrocarbon inhibitors of cytochrome P450 enzymes 1A1, 1A2, 2A6, and 2B1. Chem. Res. Toxicol., 2010, 23, 600-7.
30. Hunter, C. A.; Singh, J.; Thornton, J. M., Pi-pi interactions: the geometry and energetics of phenylalanine-phenylalanine interactions in proteins. J. Mol. Biol., 1991, 218, 837-46.
31. Ito, Y.; Kondo, H.; Goldfarb, P. S.; Lewis, D. F., Analysis of CYP2D6 substrate interactions by computational methods. J. Mol. Graph. Model., 2008, 26, 947-56.